Study of the Effectiveness of Drugs for the Treatment of Zoonotic Cutaneous Leishmaniasis in vivo on a Laboratory Model
Abstract
Confirmed evidence of sufficient effectiveness of monotherapy of zoonotic cutaneous leishmaniasis with meglumine antimonate and doxycycline in combination with interferon alpha 2b human recombinant (reaferon) has been obtained. Leishmania in the lesion was completely absent on day 60 of treatment with doxycycline. According to in vivo data, the combined therapy of experimental zoonotic cutaneous leishmaniasis in golden hamsters increased the effectiveness of meglumine antimonate and doxycycline by all parameters due to the addition of recombinant human interferon alpha 2b in comparison with monotherapy with the same drugs.
About the Author
Yu. K. Kuznetsova
Federal state budgetary institution «Polyclinic No. 2» of the Administration of the President of the Russian Federation
Russian Federation
Russian Federation
References
1. Blum J, Buffet P., Visser L., Harms G., Bailey M.S., Caumes E. et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers. J Travel Med 2014; 21: 116-129.
2. Hodiamont C., Kager P., Bart A., de Vries H.J., van Thiel P.P., Leenstra T. et al. Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis 2014; 8: e2832.
3. Van der Auwera G., Dujardin J. Species typing in dermal leishmaniasis. Clin Microbiol Rev 2015; 28: 265-294.
4. WHO, 2010. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. WHO Technical Report Series 949: 1-186.
5. Кузнецова Ю.К., Сергеев В.П., Кузнецова К.Ю. Исторические аспекты лечения кожного лейшманиоза. Антибиотики и химиотер. - 2017. - Т. 62. - № 3-4. - С. 53-57
6. Кузнецова Ю.К., Янг Д. Исторические аспекты лечения кожного лейшманиоза. Медицинская паразитология и паразитарные болезни. - 2017. - № 1. - С. 33-35
7. Tarr P.I., Aline R.F. Jr., Smiley B.L., Scholler J., Keithly J., Stuart K. LR1: a candidate RNA virus of Leishmania. Proc Natl Acad Sci USA 1988 Dec; 85 (24): 9572-5
8. Kariyawasam R, Grewal J., Lau R., Purssell A., Valencia B.M., Llanos-Cuentas A. et al. Influence of Leishmania RNA Virus 1 on Proinflammatory Biomarker Expression in a Human Macrophage Model of American Tegumentary Leishmaniasis. J Infect Dis 2017 Oct 17; 216 (7): 877-886.
9. Hajjaran H. Mahdi M., Mohebali M., Samimi-Rad K., Ataei-Pirkooh A., Kazemi-Rad E. et al. Detection and molecular identification of leishmania RNA virus (LRV) in Iranian Leishmania species. Arch Virol 2016 Dec;161 (12): 3385-3390. Epub 2016 Sep 7.
10. Hartley M.A., Drexler S., Ronet C., Beverley S.M., Fasel N. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol. 2014 Aug; 30 (8): 412-22. doi: 10.1016/j.pt.2014.05.006. Epub 2014 Jun 20.
11. Кузнецова Ю.К. Сравнительные данные противолейшманиальной активности антибактериальных препаратов отечественного производства, полученные в экспериментальных исследованиях in vitro. Здоровье населения и среда обитания. - 2017. - № 1 (286). - С. 50-51.
12. Кузнецова Ю.К. Кожный лейшманиоз: причины резистентности терапии. Проблемы медицинской микологии. - 2018. - Т. 20. - № 2
13. Masmoudi A., Dammak A., Chaaben H., Maalej N., Akrout F., Turki H. Doxycycline for the treatment of cutaneous leishmaniasis. Dermatology Online Journal 2008; 14 (8).
14. Khairulin F.Ia., Ereshov M.E., Khuseiinova Kh.Kh., Rozyreva A.A., Sukhanova T.A. Treatment of cutaneous leishmaniasis with methacycline and doxycycline (vibramycin). Vestn Dermatol Venerol 1989; 3: 62-66.
15. William H. M., Khaldoun M. Cutaneous Leishmaniasis: Recognition and Treatment. Am Fam Phys 2004; 69: 455-460.
Review
For citations:
Kuznetsova Yu.K. Study of the Effectiveness of Drugs for the Treatment of Zoonotic Cutaneous Leishmaniasis in vivo on a Laboratory Model. Antibiot Khimioter = Antibiotics and Chemotherapy. 2018;63(7-8):22-28. (In Russ.)
Views:
552
Email this article 